Citadel Advisors
NVO

Citadel Advisors’s Novo Nordisk NVO Stock Holding History

Citadel Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352M Buy
9,569,700
+1,414,200
+17% +$67M 0.06% 264
2025
Q4 		$415M Buy
8,155,500
+2,068,000
+34% +$106M 0.06% 235
2025
Q3 		$338M Buy
6,087,500
+3,151,800
+107% +$184M 0.05% 292
2025
Q2 		$203M Buy
2,935,700
+587,900
+25% +$40M 0.04% 402
2025
Q1 		$163M Sell
2,347,800
-123,700
-5% -$10.2M 0.03% 447
2024
Q4 		$213M Buy
2,471,500
+1,317,800
+114% +$143M 0.04% 385
2024
Q3 		$137M Sell
1,153,700
-253,500
-18% -$33.8M 0.03% 526
2024
Q2 		$201M Buy
1,407,200
+51,000
+4% +$6.76M 0.04% 344
2024
Q1 		$174M Buy
1,356,200
+422,900
+45% +$50.3M 0.03% 426
2023
Q4 		$96.5M Sell
933,300
-56,300
-6% -$5.57M 0.02% 703
2023
Q3 		$90M Sell
989,600
-42,800
-4% -$3.77M 0.02% 690
2023
Q2 		$83.5M Buy
1,032,400
+273,600
+36% +$22.4M 0.02% 722
2023
Q1 		$60.4M Sell
758,800
-63,600
-8% -$4.51M 0.01% 932
2022
Q4 		$55.7M Sell
822,400
-36,600
-4% -$2.15M 0.01% 1042
2022
Q3 		$42.8M Buy
859,000
+375,800
+78% +$20.1M 0.01% 1187
2022
Q2 		$26.9M Sell
483,200
-153,800
-24% -$8.53M 0.01% 1559
2022
Q1 		$35.4M Buy
637,000
+147,000
+30% +$7.54M 0.01% 1397
2021
Q4 		$27.4M Buy
490,000
+94,800
+24% +$5.14M 0.01% 1690
2021
Q3 		$19M Buy
395,200
+194,400
+97% +$9.4M ﹤0.01% 2073
2021
Q2 		$8.41M Buy
200,800
+53,200
+36% +$2.06M ﹤0.01% 3385
2021
Q1 		$4.98M Buy
147,600
+2,400
+2% +$85.5K ﹤0.01% 4269
2020
Q4 		$5.07M Buy
145,200
+115,600
+391% +$4M ﹤0.01% 3663
2020
Q3 		$1.03M Sell
29,600
-203,200
-87% -$6.77M ﹤0.01% 5982
2020
Q2 		$7.62M Buy
232,800
+82,000
+54% +$2.62M ﹤0.01% 2545
2020
Q1 		$4.54M Sell
150,800
-21,800
-13% -$649K ﹤0.01% 2860
2019
Q4 		$5M Sell
172,600
-78,200
-31% -$2.17M ﹤0.01% 3078
2019
Q3 		$6.48M Sell
250,800
-20,400
-8% -$516K ﹤0.01% 2754
2019
Q2 		$6.92M Buy
271,200
+109,400
+68% +$2.7M ﹤0.01% 2641
2019
Q1 		$4.23M Sell
161,800
-161,600
-50% -$3.97M ﹤0.01% 3243
2018
Q4 		$7.45M Buy
323,400
+144,800
+81% +$3.22M ﹤0.01% 2245
2018
Q3 		$4.21M Sell
178,600
-35,000
-16% -$854K ﹤0.01% 3217
2018
Q2 		$4.93M Buy
213,600
+143,800
+206% +$3.42M ﹤0.01% 2799
2018
Q1 		$1.72M Buy
69,800
+25,200
+57% +$662K ﹤0.01% 3969
2017
Q4 		$1.2M Sell
44,600
-24,200
-35% -$615K ﹤0.01% 4396
2017
Q3 		$1.66M Sell
68,800
-123,800
-64% -$2.8M ﹤0.01% 3633
2017
Q2 		$4.13M Buy
192,600
+68,800
+56% +$1.39M ﹤0.01% 2325
2017
Q1 		$2.12M Buy
123,800
+57,400
+86% +$999K ﹤0.01% 3005
2016
Q4 		$1.19M Sell
66,400
-31,200
-32% -$566K ﹤0.01% 3631
2016
Q3 		$2.03M Sell
97,600
-42,200
-30% -$1.05M ﹤0.01% 2953
2016
Q2 		$3.76M Buy
+139,800
New +$3.83M ﹤0.01% 2090

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Citadel Advisors's NVO Position: Q1 2026 in Review

Citadel Advisors reduced its Novo Nordisk (NVO) stake by 63% in Q1 2026, selling an estimated $221M and leaving 2,736,525 shares worth $101M. The position accounts for 0.02% of the portfolio, ranked #805.

Citadel Advisors first reported a position in NVO in Q3 2014 and has held it in 45 quarters since. The position peaked at $377M in Q4 2025. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Citadel Advisors held 2,736,525 shares of Novo Nordisk worth $101M as of Q1 2026.
  • Citadel Advisors sold 4,674,398 Novo Nordisk shares in Q1 2026, an estimated $221M.
  • Novo Nordisk made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #805 holding.
  • Citadel Advisors first reported a position in Novo Nordisk in Q3 2014 and has held it in 45 quarters since.
  • Citadel Advisors's Novo Nordisk position peaked at $377M in Q4 2025.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.